TAM
ATXS

Tocqueville Asset Management’s Astria Therapeutics ATXS Stock Holding History

Tocqueville Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-333
Closed -$123K – 809
2016
Q3 		$123K Buy
+333
New +$87.7K ﹤0.01% 801
2016
Q1 		– Sell
-750
Closed -$357K – 866
2015
Q4 		$357K Buy
750
+250
+50% +$120K ﹤0.01% 736
2015
Q3 		$243K Buy
+500
New +$357K ﹤0.01% 861

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tocqueville Asset Management's ATXS Position: Q4 2016 in Review

Tocqueville Asset Management sold out of Astria Therapeutics (ATXS) in Q4 2016, closing a stake of 333 shares — an estimated $123K sold.

Tocqueville Asset Management first reported a position in ATXS in Q3 2015 and held it in 3 quarters. The position peaked at $357K in Q4 2015. 26 funds tracked by Wall St. Rank hold ATXS as of Q4 2016.

  • Tocqueville Asset Management reported no remaining Astria Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Tocqueville Asset Management sold 333 Astria Therapeutics shares in Q4 2016, an estimated $123K.
  • Tocqueville Asset Management first reported a position in Astria Therapeutics in Q3 2015 and held it in 3 quarters.
  • Tocqueville Asset Management's Astria Therapeutics position peaked at $357K in Q4 2015.
  • 26 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2016.

Based on Tocqueville Asset Management's 13F filing for Q4 2016, filed 30 Jan 2017.